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a  b  s  t  r  a  c  t
Background:  Both  the  prevalence  of atrial  ﬁbrillation  and  coronary  artery  disease  (CAD)  is  increasing  in
aged societies.  However,  limited  data  are  available  regarding  the  prevalence  of  CAD  and  the  incidence  of
coronary  events  in  Japanese  patients  with  nonvalvular  atrial  ﬁbrillation  (NVAF).
Methods and  results:  The  data  in  this  study  were  derived  from  Shinken  Database  2004–2010,  which
includes  15,227  new  patient  visitors  to the  Cardiovascular  Institute  between  June  2004  and  March  2011.
In  the  database,  1835  patients  were  diagnosed  with  NVAF  (mean  age  63  years,  mean  CHADS2  score
1.1  ± 1.1,  and  75%  were  men).  The  prevalence  of  CAD  at the initial  visit  was 118 patients  (6.4%).  They
were  older  age  and  had  a greater  prevalence  of men,  more  history  of congestive  heart  failure  and  more
history  of cardiovascular  risk  factors  rather  than  those  without.  During  the  follow-up  period  of  532 ± 599rognosis days,  coronary  events  (myocardial  infarction,  unstable  angina,  and  stable  angina)  occurred  in  51 patients
(1.9%/year).  Multivariate  analysis  showed  that a  history  of  CAD  (p  <  0.001)  and  older  age  (p =  0.024)  were
independent  predictors  of  the incidence  of future  coronary  events.
Conclusions:  In Japanese  patients  with  NVAF,  both  the  presence  of  CAD  and  the  occurrence  of coronary
events  are  not  uncommon.  History  of  CAD  and  older  age  are  strongly  associated  with  the  incidence  of
coronary  events.
©  2013  Published  by  Elsevier  Ltd on  behalf  of Japanese  College  of Cardiology.ntroduction
Atrial ﬁbrillation (AF) is the most common cardiac arrhythmia in
linical practice. AF is associated with multiple symptoms, with sig-
iﬁcant morbidity and mortality and with decreased quality of life.
he prevalence of AF in the US population is expected to increase
rom 2.3 million in 2001 to 5.6 million in 2050 [1]. Since the current
revalence of AF is somewhat lower or comparable to that observed
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ttp://dx.doi.org/10.1016/j.jjcc.2013.08.007in Western countries, the AF population is expected to increase
also in Japan. The mortality rate of AF patients is almost twice
that of patients with normal sinus rhythm. Notably, this obser-
vation has been attributed to an increased cardiac death due to
underlying heart disease [2–5] rather than to thromboembolism
[6].
In Western countries, coronary artery disease (CAD) is highly
prevalent among patients with AF and may be one of its under-
lying causes [7]. Furthermore, AF may  be the sole manifestation
of CAD [8]. Interestingly, epidemiological data have indicated that
ischemic heart disease is one of the most common underlying
causes of death among patients with AF [9]. These observations
have therefore led to an increased interest in the evaluation of
underlying CAD in patients with nonvalvular atrial ﬁbrillation
(NVAF).
The present study aimed to investigate the prevalence of CAD
and the incidence of coronary events in Japanese patients with
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tudy patients
The Shinken database comprises all new patients visiting the
ardiovascular Institute in Tokyo, Japan (“Shinken” is an abbrevi-
ted name in Japanese for the name of the hospital), and excludes
atients with active cancer and any foreign travellers. The principal
im of this hospital-based database is surveillance of the preva-
ence and prognosis of cardiovascular diseases in the urban areas of
apan [10–12]. The registry started in June 2004, and patients have
een continually registered to the database annually thereafter.
nformation about patients’ health status and the incidence of car-
iovascular events and mortality are maintained in the database by
ts link to the hospital’s medical records and by a mail enquiry sent
o patients approximately once or twice per year. The data in the
resent study were derived from this database between June 2004
nd March 2010 (Shinken Database 2004–2010), which included
5,227 new visiting patients. The database contained 1835 patients
ith the diagnosis of NVAF.
ata collection
For each patient, an electrocardiogram and a chest radiograph
ere obtained, and the cardiovascular status was  then evaluated
sing echocardiography, exercise test, and 24-h Holter monitor
ecords from the initial visit according to the attending physicians.
he following information was collected from the database: (1)
atient data (age, sex, and type of AF), (2) cardiovascular diseases,
3) cardiovascular risk factors, and (4) use of medications. The body
ass index was calculated as weight in kilograms divided by height
n meters squared. The CHADS2 score is calculated by adding 1 point
ach for congestive heart failure, hypertension, age ≥75 years, and
iabetes mellitus, and by adding 2 points for a previous stroke or
ransient ischemic attack [13]. In the present study, patients were
ivided into 3 CHADS2 score categories (0, 1, and ≥2).
eﬁnitions of AF, CAD, and coronary events
In the present study, AF was diagnosed based on electro-
ardiography at the initial visit, which included 12-lead surface
lectrocardiograms or 24-h Holter monitor records. AF was also
iagnosed based on any medical history of AF from referring physi-
ians.
The deﬁnition of CAD included: (1) history of percutaneous coro-
ary intervention (PCI) or coronary artery bypass graft (CABG) and
2) ≥50% coronary stenosis as documented by coronary angiogra-
hy (CAG) results and the detection of ischemia on stress testing
ncluding the treadmill stress test, radioisotope single-photon
mission computed tomography, and/or fractional ﬂow reserve
FFR) during CAG. FFR, an index of coronary stenosis severity, can be
alculated from the ratio of hyperemic distal to proximal coronary
ressure.
Coronary events were deﬁned as hospitalization for myocar-
ial infarction, unstable angina, or stable angina. The incidence of
oronary events was presented using the person-year method.
tatistical analysis
In baseline characteristics, continuous variables and categorical
ariables are expressed as mean ± SD and absolute numbers (per-
entage), respectively. A chi-square test and an unpaired Student’s
-test were used for the comparison of categories and continuous
ariables between 2 groups, respectively. The cumulative incidence
f coronary events was estimated by the Kaplan–Meier method. The
ncidence of coronary events according to the signiﬁcant univariateology 63 (2014) 123–127
variables was  calculated by the person-year methods. Univari-
ate and multivariate Cox regression analyses were performed to
identify the predictors for the incidence of coronary events. In mul-
tivariate model, co-factors signiﬁcantly associated with incidence
of coronary events in the univariate models were considered in
the stepwise method. All statistical analyses were performed using
SPSS (SPSS Inc., Chicago, IL, USA) for Windows (Microsoft Corp.,
Redmond, WA,  USA), version 19.0 software. Statistical signiﬁcance
was set at p < 0.05.
Ethical issues
The ethical committee at the Cardiovascular Institute granted
ethical permission for this study, and all the patients provided writ-
ten informed consent.
Results
Characteristics of the total study patients
Table 1 shows the baseline characteristics of the study patients.
In this study, 1835 patients (age, 63.2 ± 12.6 years; 1388 men) were
enrolled. Among them, 45.4% had tobacco use (current and past),
44.9% hypertension, 25.2% dyslipidemia, and 16.3% diabetes melli-
tus. The mean CHADS2 score of the study patients was 1.1 ± 1.1
(CHADS2 = 0, n = 685; CHADS2 = 1, n = 589; CHADS2 ≥ 2, n = 561).
Forty-seven percent of patients were treated with warfarin, and
39% with aspirin.
Prevalence of CAD
In the total study patients, patients with a history of CAD were
118 (6.4%) at the initial visit. They were older age and had a higher
prevalence of men, more history of congestive heart failure and
more history of cardiovascular risk factors than those without.
Additionally, they had higher CHADS2 score than those without
(2.3 ± 1.2 vs. 1.0 ± 1.1, p < 0.001).
Incidence of coronary events
During the follow-up of 532 ± 599 days, 51 patients (1.9%/year)
experienced coronary events. The Kaplan–Meier curves for the
incidence rate of coronary events are shown in Fig. 1. Oral anti-
coagulants prescription was  not associated with the incidence of
coronary events in this study. Univariate Cox regression analysis
showed that older age (p = 0.002), men  (p = 0.048), hypertension
(p = 0.004), diabetes mellitus (p = 0.004), history of heart fail-
ure (p = 0.004), history of CAD (p < 0.001), and CHADS2 score ≥ 2
(p < 0.001) were associated with the incidence of coronary events
(Table 2). Multivariate Cox regression analysis including univari-
ate factors showed that older age (p = 0.024) and history of CAD
(p < 0.001) were the independent determinants of incidence of
coronary events (Table 3). We  demonstrated the incidence of coro-
nary events according to the signiﬁcant univariate values (Fig. 2).
Among them, coronary events occurred more frequently in patients
with conventional coronary risk factors (i.e. older age, men, hyper-
tension, diabetes mellitus, history of congestive heart failure) and a
history of CAD. In addition, coronary events occurred in 11 patients
(1.1%/year) in the CHADS2 = 0, 12 (1.4%/year) in CHADS2 = 1, and
28 (3.6%/year) in CHADS2 ≥ 2, respectively. Hence, there was  a sig-
niﬁcant linear trend between CHADS2 scores and annual coronary
events rate.
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Table  1
Patient characteristics.







Age ± SD (years) 70.0 ± 9.4 62.8 ± 12.6 63.2 ± 12.6 <0.001
Male  (%) 103 (87.3) 1285 (74.8) 1388 (75.6) 0.001
BMI  24.2 ± 3.2 23.8 ± 3.5 23.9 ± 3.5 0.355
Type  of AF
First-detected 40 (33.9) 428 (24.9) 468 (25.5) 0.022
Paroxysmal 32 (27.1) 748 (43.6) 780 (42.5) <0.001
Persistent 11 (9.3) 184 (10.7) 195 (10.6) 0.387
Permanent 35 (29.7) 357 (20.8) 392 (21.4) 0.018
CHADS2 score
0 7 (5.9) 678 (39.5) 685 (37.3) <0.001
1  23 (19.5) 566 (33.0) 589 (32.1) 0.001
≥2  88 (74.6) 473 (27.5) 561 (30.6) <0.001
Cardiovascular diseases
History of congestive heart failure 80 (67.8) 231 (13.5) 311 (16.9) <0.001
History of TIA/stroke 12 (10.2) 103 (6.0) 115 (6.3) 0.06
Cardiovascular risk factors
Smoking 63 (53.4) 771 (44.9) 834 (45.4) 0.045
Dyslipidemia 69 (58.5) 393 (22.9) 462 (25.2) <0.001
Hypertension 81 (68.6) 743 (43.3) 824 (44.9) <0.001
Chronic kidney disease 46 (39.0) 449 (26.2) 495 (27.0) 0.002
Diabetes mellitus 48 (40.7) 251 (14.6) 299 (16.3) <0.001
Medication at discharge
Aspirin 95 (80.5) 626 (36.5) 721 (39.3) <0.001
Thienopyridine 69 (58.5) 43 (2.5) 112 (6.1) <0.001
Warfarin 71 (60.2) 796 (46.4) 867 (47.2) 0.002
Beta-blockers 72 (61.0) 543 (31.6) 615 (33.5) <0.001
Calcium channel blocker 33 (28.0) 256 (14.9) 289 (15.7) <0.001
Digitalis glycosides 27 (22.9) 263 (15.3) 290 (15.8) 0.024
Diuretics 55 (46.6) 324 (18.9) 379 (20.7) <0.001
RAS  inhibitors 72 (61.0) 494 (28.8) 566 (30.8) <0.001
Statin 58 (49.2) 176 (10.3) 234 (12.8) <0.001
AF, atrial ﬁbrillation; CAD, coronary artery disease; BMI, body mass index; CHADS2 score, congestive heart failure, hypertension, age > 75, diabetes mellitus, stroke or TIA;
TIA,  transient ischemic attack; RAS, renin-angiotensin system.
Fig. 1. The Kaplan–Meier curve for the incidence of coronary events. Coronary events represent myocardial infarction, unstable angina, and stable angina.
126 K. Senoo et al. / Journal of Cardi
Table  2
Univariate analysis for the incidence of coronary events.
Hazard ratio 95% CI p-Value
Univariate analysis
Age 1.040 1.015–1.066 0.002
Sex,  men  2.237 1.007–4.968 0.048
Body mass index 1.023 0.932–1.123 0.631
Smoking 1.160 0.662–2.032 0.603
Hypertension 2.304 1.306–4.067 0.004
Dyslipidemia 1.599 0.893–2.862 0.155
Diabetes mellitus 2.414 1.336–4.362 0.004
Chronic kidney disease 1.531 0.862–2.719 0.147
History of stroke or TIA 1.056 0.329–3.391 0.928
History of heart failure 2.337 1.305–4.183 0.004
History of CAD 9.234 5.188–16.432 <0.001
CHADS2 score = 0 Reference
CHADS2 score = 1 1.295 0.572–2.936 0.535
CHADS2 score ≥ 2 3.266 1.626–6.562 0.001
TIA, transient ischemic attack; CAD, coronary artery disease; CHADS2 score, conges-
tive heart failure, hypertension, age > 75, diabetes mellitus, stroke or TIA.
Table 3
Multivariate analysis for the incidence of coronary events.
Hazard ratio 95% CI p-Value
Multivariate analysis
History of CAD 9.234 5.188–16.432 <0.001
Age 1.031 1.005–1.058 0.021













(ig. 2. The incidence of coronary events according to the signiﬁcant univariate
aluables. CHF, congestive heart failure; CAD, coronary artery disease.
iscussion
In the present study, we have shown that both the prevalence
f CAD and the incidence of coronary events are not uncommon in
ur Japanese NVAF patients. This is the ﬁrst study to examine the
revalence of CAD and the incidence of coronary events in Japanese
VAF patients.
revalence of CAD and incidence of coronary events in NVAF
atients
In several reports from Western countries [14–17], the preva-
ence of CAD in AF patients has been reported to be 18–34%. In
ontrast, the prevalence of CAD in the present study was  rela-
ively low (6.4%), in accordance with previous Japanese studies
7–8%) [10,18,19]. The overall incidence rate of coronary eventsology 63 (2014) 123–127
in Japanese patients has long been unknown. The present study
revealed that it was  1.9%/year in NVAF patients, which was  also
relatively low compared with previous Western reports (3.1%/year)
[20]. The differences in the prevalence of CAD and incidence of coro-
nary events in NVAF patients between Japan and Western countries
are not clear, but might be linked to differences in patients’ back-
grounds. Actually, the distribution of CHADS2 scores was  different.
In the present study, low-risk patients (0 or 1 points) accounted
for approximately 70% of the total, while low-risk patients with
CHADS2 scores of 0 or 1 accounted for approximately 17–53% of
the subjects in the previous Western reports [21–23].
The independent predictors of the incidence of coronary events
were a history of CAD and older age, in this study. Although a causal
relationship between CAD and AF was  not yet investigated, patients
with a history of CAD were strongly associated with future coronary
events, suggesting greater CAD burden conferred a signiﬁcantly
higher risk for clinical plaque progression. Second, age steadily
increases the absolute baseline risk of coronary events independent
of the conventional risk factors. Therefore, patients without risk
factors will tend to present at a much later age once their baseline
absolute risk increases sufﬁciently to cause a signiﬁcant prevalence
of disease.
AF and CAD
CAD is highly prevalent among patients with AF and may  be
one of its etiologic factors in Western countries [7]. Once AF is
diagnosed, the presence of CAD is shown to be related to recurrent
AF episodes [24], to the presence of symptoms (including arrhyth-
mic, heart failure, and angina symptoms) [25], and to increased
risk of death [26,27]. Therefore, CAD plays an important role in the
mortality and quality of life of patients with NVAF.
Additionally, there are mechanistic reasons for the link between
AF and CAD. AF has been shown to independently increase sys-
temic inﬂammation as measured by C-reactive protein (CRP) level,
which increases with increasing CHADS2 score [28]. In addition,
higher CRP levels were found to be associated with a signiﬁcantly
increased risk for coronary events, including death, myocardial
infarction, or unstable angina pectoris [29]. These results may
suggest that the CHADS2 score reﬂects blood stasis and the pres-
ence of systemic inﬂammation, which causes left atrial endothelial
damage, dysfunction, and, ﬁnally, cardiovascular events. In the
present study, we  additionally found that the prevalence of CAD
increased with an increase in CHADS2 score, and that the inci-
dence of coronary events was  also higher with increasing CHADS2
score. Among components of the CHADS2 score, older age, hyper-
tension, and diabetes are also well-recognized risk factors for CAD.
In fact, the REACH study [22] also found that the CHADS2 score
classiﬁcation was useful in predicting not only stroke but also car-
diovascular death in stable outpatients with established or at high
risk of atherothrombosis. Therefore, the prevention of both stroke
and coronary events, and more intensive antithrombotic therapy,
would be needed for NVAF patients with high CHADS2 scores. How-
ever, the risk of hemorrhage increases in case of combined use of
an anticoagulant and antiplatelet drugs [30,31]. In such cases, spe-
cial attention for the safe management of antithrombotic therapy
would be necessary, which has been already proposed in a recent
bleeding risk assessment guideline from the European Society of
Cardiology in 2010 [32].
LimitationsThe present study is limited by its retrospective nature; the
results should be conﬁrmed by prospective cohort studies. Second,
the population was  limited to patients visiting a single cardiovas-
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e extrapolated to the general population. Therefore, these results
hould be re-examined in population-based studies. Third, we ana-
yzed only patients with AF, therefore it was unclear that AF itself
elated to the incidence of coronary events. Finally, in the present
tudy, AF was diagnosed by medical history and clinical exami-
ations, including electrocardiograms and Holter recordings. This
ethod is well known to underestimate AF prevalence, because
symptomatic AF is neglected [24].
onclusion
In our Japanese population, both the prevalence of CAD and the
ncidence of coronary events are not uncommon in patients with
VAF. History of CAD and older age are strongly associated with
he incidence of coronary events.
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